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Abstract
Background: Classical NF-kB signaling functions as a negative regulator of skeletal myogenesis through potentially multiple
mechanisms. The inhibitory actions of TNFa on skeletal muscle differentiation are mediated in part through sustained NF-kB
activity. In dystrophic muscles, NF-kB activity is compartmentalized to myofibers to inhibit regeneration by limiting the
number of myogenic progenitor cells. This regulation coincides with elevated levels of muscle derived TNFa that is also
under IKKb and NF-kB control.
Methodology/Principal Findings: Based on these findings we speculated that in DMD, TNFa secreted from myotubes
inhibits regeneration by directly acting on satellite cells. Analysis of several satellite cell regulators revealed that TNFa is
capable of inhibiting Notch-1 in satellite cells and C2C12 myoblasts, which was also found to be dependent on NF-kB.
Notch-1 inhibition occurred at the mRNA level suggesting a transcriptional repression mechanism. Unlike its classical mode
of action, TNFa stimulated the recruitment of Ezh2 and Dnmt-3b to coordinate histone and DNA methylation, respectively.
Dnmt-3b recruitment was dependent on Ezh2.
Conclusions/Significance: We propose that in dystrophic muscles, elevated levels of TNFa and NF-kB inhibit the
regenerative potential of satellite cells via epigenetic silencing of the Notch-1 gene.
Citation: Acharyya S, Sharma SM, Cheng AS, Ladner KJ, He W, et al. (2010) TNF Inhibits Notch-1 in Skeletal Muscle Cells by Ezh2 and DNA Methylation Mediated
Repression: Implications in Duchenne Muscular Dystrophy. PLoS ONE 5(8): e12479. doi:10.1371/journal.pone.0012479
Editor: Mary Bryk, Texas A&M University, United States of America
Received December 15, 2009; Accepted August 1, 2010; Published August 30, 2010
Copyright:  2010 Acharyya et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for this study was obtained from a Muscular Dystrophy Association award (DCG) and an OSU University Presidential Fellowship (SA). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: denis.guttridge@osumc.edu
¤ Current address: Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
Introduction
Adult skeletal muscle represents a dynamic tissue in our body
that possesses a remarkable capacity to regenerate in response to
injury [1,2]. A normal regenerative response in muscle involves
activation and subsequent proliferation of quiescent satellite cells
that eventually differentiate and fuse to form new myofibers.
However, in pathological states such as muscular dystrophies,
satellite cell number as well as their doubling potential are thought
to decrease, resulting in impaired regenerative potential [3,4].
Duchenne muscular dystrophy (DMD) is one such severe
myopathy that arises from mutations in the 2.5 Mb DMD gene
and is lethal in late childhood due to secondary consequences such
as persistent muscle degeneration, exhausted regenerative capacity
and respiratory or cardiac failure [5]. The DMD gene codes for a
427 KDa protein, dystrophin that is thought to be critical in
maintaining a mechanical as well as signaling link from the
extracellular matrix to the cytoskeleton in a muscle cell. The
absence of dystrophin in DMD results in progressive muscle
weakness, frequent contractures, paucity of regenerating fibers and
gradual replacement of muscle fibers with adipose and connective
tissue. Despite the advances in understanding the proximate causes
of DMD, correcting the primary defect has proven to be a
daunting task, with no curative therapy options available against
this deadly disease [6].
Althoughstemming froma single cause, DMDisnow increasingly
being accepted as multifactorial in progression, with a myriad of
signaling pathways influencing its pathological state. The nuclear
factor kappa B (NF-kB) pathway represents one such signaling
pathway that has been recently linked to both inflammatory
responses as well as attenuated regeneration [7,8]. In mammalian
cells, the NF-kB family of transcription factors consists of five
subunits namely p65 or RelA, RelB, c-Rel, p50 and p52, which
either homo or heterodimerize with each other. In an unstimulated
state, NF-kB exists as a latent complex bound to the inhibitor family
of proteins or IkB proteins. Upon stimulation with classical inducing
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IL1b, an upstream IkB kinase complex (IKK) is activated, which
results in the phosphorylation and degradation of the IkBp r o t e i n s ,
releasing the NF-kB dimer to translocate to the nucleus to activate
transcription [9,10]. Depending on the physiological conditions,
stimulus and the cell type, the NF-kB signaling pathway maintains a
negative feedback loop by activating the transcription of IkBa that
re-sequesters the NF-kB complex in the cytoplasm or a positive
feedback loop by synthesizing its own inducer, TNF, that can
reactivate the pathway [11,12].
Primarily implicated in immune responses, NF-kB has been also
shown to negatively regulate skeletal muscle differentiation
[13,14,15]. NF-kB is constitutively active in proliferating myo-
blasts and can inhibit myogenesis by promoting a mitogenic
activity via cyclin D1 or by inhibiting the synthesis of MyoD, a
bHLH transcription factor that functions in muscle development
and repair [16,17,18]. More recently, NF-kB was shown to
suppress myofibrillar and miRNA-29 gene expression through the
regulation of the transcriptional repressor, YY1 [19]. Moreover,
treatment of primary myoblasts with the NF-kB inhibitor,
curcumin stimulates myoblast fusion thereby enhancing myogen-
esis [20]. In line with these in vitro findings, activation of the TNF
pathway by muscle gene transfer inhibits regeneration in vivo
while muscle specific deletion of IKK was recently described to
promote secondary myogenesis in response to acute injury signals
[21,22].
Elevated levels of inflammatory mediators such as TNF have
been also associated with persistent NF-kB activation under
chronic injury conditions in both DMD patients and mdx mice
[23,24]. We recently showed that conditional deletion of IKKb in
mdx muscle cells decreases TNF expression, which was associated
with a concomitant elevation of Pax7
+, CD34
+ satellite cells [25].
Since chronic levels of TNF functions as a potent inhibitor of
muscle differentiation, it suggests that this cytokine might take part
in limiting the regenerative potential of muscle stem cells in
dystrophic muscle. Results from this study support this notion, as
TNF is able to downregulate Notch-1, a key determinant of
satellite cell activation [26]. We find that in vitro, TNF represses
Notch-1 in an NF-kB dependent manner. In addition, deletion of
IKKb in mdx mice restores Notch-1 levels. Furthermore, distinct
from the usual TNF response, we show that TNF repression
occurs via a combination of histone and DNA methylation on the
Notch-1 promoter. Together, these findings demonstrate a novel
activity of TNF for epigenetic regulation of chromatin silencing.
We further propose that TNF-mediated repression of Notch
functions in dystrophic muscles to limit satellite cell regeneration.
Results
TNF inhibits Notch-1 expression
Recently, we reported on the role of the IKK/NF-kB signaling
pathway in the mdx model of muscular dystrophy [25]. Specifically,
we demonstrated using mutant mice deficient in skeletal muscle
derived IKKb that NF-kB signaling functions in dystrophic muscle
to limit the regenerative potential of muscle satellite cells. We also
found that this regulation coincided with elevated levels of TNF,
leading us to speculate that TNF production by NF-kB is muscle
derived and acts in paracrine fashion to suppress myogenesis of
satellite cells. To explore this notion, freshly isolated, pre-plated
mononuclear cells from mdx muscles were treated with TNF and
analyzed for differences in genes Pax7, c-met, syndecan-4, M-
cadherin, and Notch-1, which are important regulators of satellite
cell specification, biogenesis, migration, and adhesion. Results
showed that TNF had no effect on Pax7, c-met, syndecan-4, or
m-cadherin (Fig. 1A). In contrast, cytokine treatment caused a
significant reduction in Notch-1 expression (Fig. 1A), a result that
we confirmed by both quantitative RT-PCR and western blotting
(Fig. 1B and 1C). This regulation appeared specific to Notch-1
since its closely related homolog, Notch-2 was unaffected by TNF
(data not shown). Since mononuclear cells represent a mixed
population, we repeated our analysis with enriched satellite cells by
FACS sorting for CD34
+, a7integrin
+, Sca1
2 cells, and again
observed in duplicate experiments that Notch-1 was downregu-
lated by TNF (Fig. 1D). In addition, TNF reduced Notch-1 in
C2C12 myoblasts (Fig. 1E) suggesting that this regulation is not
selective to mdx progenitor muscle cells. Moreover, Notch-1
transcriptional target genes, Hes-1 and Hey-1 were also signifi-
cantly affected (Fig. 1E), further indicating that TNF mediates
repression on Notch-1 signaling.
This activity of the Notch signaling is initiated by binding of
Notch ligands such as Delta and Jagged to the notch receptor,
which in turn leads to an enzymatic cleavage of the receptor and
release of the activated Notch-1 protein known as Notch
intracellular domain (NICD) into the cytoplasm [27]. NICD then
translocates to the nucleus and binds to transcription factors such
as RBP-J and Suppressor of Hairless Su(H). The Notch signaling
pathway is additionally regulated by increased expression of its
inhibitor, Numb that can antagonize the activity of NICD
preventing its nuclear translocation [28]. To determine whether
TNF affects other components of Notch signaling, we examined
the levels of Notch-1 and its activated form, NICD. As predicted
from the downregulation of Notch-1 mRNA, and total Notch
receptor protein (Fig 1A and 1C), the NICD form of Notch-1 was
also strongly downregulated by TNF in C2C12 myoblasts (Fig. 1F).
However, the levels of the ligands, Delta and Jagged as well as the
Notch inhibitor, Numb remained unchanged, indicating that TNF
mediated repression of Notch-1 is independent of its ligands or
inhibitor levels.
Next, we examined Notch-1 levels in IKKb deleted mdx muscles
which were found to express less TNFa [25]. Results showed that
Notch-1 was increased in these muscles compared to mdx IKKb
flox control littermates (Fig. 2A). To further evaluate the effect of
TNF on Notch-1 in the context of muscle regeneration, tibialis
anterior muscles were injured with cardiotoxin injection in mice
that had previously been implanted subcutaneously with vector
control or TNF secreting Chinese hamster ovary (CHO) cells that
developed as a localized tumor [29]. Whereas cardiotoxin induced
Notch-1 in control mice at levels that persisted over 4 days, this
regulation was noticeably blunted in mice expressing TNF
(Fig. 2B). Together these data are suggestive that Notch-1 is a
target of TNF in vivo.
TNF requires NF-kB to down regulate Notch-1
Although TNF is a pleiotropic factor, much of its signaling
potential occurs through pathways like NF-kB [9]. We therefore
asked whether NF-kB activity was required for TNF mediated
regulation of Notch-1. Results showed that compared to control
treated myoblasts, cells inhibited in NF-kB through expression of
the degradation resistant IkBa-SR mutant retained Notch-1
expression upon TNF treatment (Fig. 3A). To confirm this
regulation, C2C12 myoblasts were treated with TNF in the
presence of the specific inhibitor of the IKK complex, the Nemo
Binding Domain (NBD) peptide [30]. Results showed that wild
type NBD, but not mutant peptide or a PI3K/Akt inhibitor
(wortmannin), blocked Notch-1 suppression by TNF (Fig. 3B).
These data support the requirement of NF-kB in TNF-mediated
repression of Notch-1.
TNF Inhibition of Notch-1
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Ezh2
To gain further insight into the mechanism of Notch-1
regulation, C2C12 myoblasts were treated with TNF and the
kinetics of Notch-1 expression was examined. Results revealed that
Notch reduction occurred slowly reaching maximum suppression
by 24 hrs (Fig. 4A). Given that NF-kB activation in response to
TNF occurs normally within minutes, it suggested that another
mechanism indirect of NF-kB might be involved. This led us to
investigate whether co-repressor complexes could act in the
transcriptional silencing of Notch-1. One such co-repressor
complex that was explored was the histone deacetylases (HDACs)
that are typically found associated with mSin3 or NuRD and are
often recruited to promoters to silence their expression [31,32].
However, pretreatment of C2C12 myoblasts with the HDAC
inhibitor, Trichostatin A at different doses did not restore Notch-1
levels in the presence of TNF (data not shown). In addition,
chromatin immunoprecipitation assay (ChIP) with HDAC-1,
mSin3 or Mi2 antibodies at three different regions of the Notch-
1 promoter did not show any differences in binding upon TNF
treatment (data not shown), arguing against the possibility of
histone deacetylase involvement.
Another repressor complex regulating transcriptional silencing
is the Polycomb Group (PcG), composed of proteins such as
Enhancer of Zeste homolog 2 (Ezh2), Suppressor of Zeste12 and
embryonic ectoderm development [33]. Histone methylation is
thought to be one of the primary mechanisms of transcriptional
repression by the PcG as shown in the case of inactivation of the
X-chromosome. To access the role of the PcG in Notch-1
regulation, we performed a bioinformatic analysis of the Notch-1
promoter to delineate regions of interest based on their
conservation, CpG content, and position relative to the transcrip-
tion start site (TSS). Three regions were chosen including a
conserved site approximately 1 kb upstream of the TSS (desig-
Figure 1. TNF regulates Notch-1 expression. A. Mononuclear cell cultures were prepared from mdx muscles and cultured under proliferation
conditions and either left untreated or treated with TNF. After 24 hrs cells were harvested and processed for total RNA, and subsequently semi-
quantitative RT-PCR reactions were performed probing for satellite cell markers. GAPDH was used as a control. B. Quantitative real-time RT-PCR
analysis of Notch-1 from satellite cell cultures untreated and treated with TNF. Values shown were normalized to GAPDH levels. Asterisk denotes
statistical significance, p=0.03708. C. Western blot analysis probing for total Notch-1 receptor from duplicate mdx satellite cell cultures treated with
TNF. The blot was stripped and re-probed for a-tubulin used as a loading control D. Quantitative real-time RT-PCR was repeated as in (B) from FACS
sorted mononuclear cells enriched for a CD34
+, a7integrin
+, Sca1
2 population. E. C2C12 myoblasts were cultured under proliferating conditions and
either not treated or treated with TNF. Total RNA was prepared and quantitative RT-PCR analysis was performed probing for Notch-1 and Notch-1
targets, Hes-1 and Hey-1. Asterisk denotes statistical significance; Notch-1, p=0.04844; Hes-1, p=0.001; Hey-1, p=0.0149. F. C2C12 myoblasts were
cultured in treated in duplicate with TNF and protein lysates were subsequently probed with the intercellular activated form of Notch-1 (NICD), or
with Notch signaling components, Delta and Jagged-1.
doi:10.1371/journal.pone.0012479.g001
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the TSS (designated 105) and a third region approximately 10 kb
downstream of the TSS (designated 92) (Fig. 4B). Next, we
performed ChIP analysis with Ezh2 followed by probe-based
PCR, using primers amplifying the regions of interest. Both semi-
and quantitative amplification revealed that TNF treatment
stimulated Ezh2 association with region 105 that maps specifically
between nucleotides 2309 to 2223 of the Notch-1 promoter
(Fig. 4C and 4D). This association was time dependent and
selective, since Ezh2 binding was maximal at 24 hrs and not
observed with regions 92 or 68. Interestingly, although NF-kB has
been shown to regulate YY1 to silence myofibrillar genes, such as
troponin and myosin isoforms and miR-29 in progenitor
myoblasts [19], ChIP analysis in response to TNF found that this
PcG associated protein was not recruited with Ezh2, nor were we
able to find YY1 binding sites within this region of the Notch-1
promoter (data not shown).
Since Ezh2 is a methyltransferase that has high binding
specificity for lysine 27 in histone H3 (H3K27) [34,35,36], we
asked whether Ezh2 binding to the Notch-1 promoter translated to
its functional activity. ChIPs performed on region 105 detected an
increase in H3K27 methylation after 24 hrs of TNF treatment
(Fig. 4E). Significantly, this methylation coincided with Ezh2
binding and Notch-1 downregulation. To test the requirement of
Ezh2 for TNF-mediated repression of Notch-1, we transfected
C2C12 myoblasts with siRNA targeting Ezh2. Western blotting
confirmed the efficiency of Ezh2 knockdown (Fig. 4F), and
compared to scrambled siRNA control, silencing of Ezh2 restored
Notch-1 expression in the presence of TNF (Fig. 4G). Although
the level of Notch-1 restoration was admittedly modest, this most
likely reflects the degree to which Ezh2 silencing was achieved by
transfection of siRNA oligonucleotides. Taken together, these
results suggest that in response to TNF, Ezh2 is recruited to the
Notch-1 promoter, which catalyzes the addition of methyl groups
to H3K27 and directs a repressed chromatin state resulting in the
downregulation of Notch.
TNF promotes DNA methylation on the Notch-1
promoter
Histone methylation is often thought to act as a recruitment
platform for DNA methylation to occur [37]. Therefore, in the final
part of the study, we addressed whether Notch-1 promoter silencing
by TNF also involved methylation of CpG dinucleotides. Bisulfite
sequencing was performed on the Notch-1 promoter surrounding
the Notch-1 TSS, but outside region 105 (designated region BS2,
Fig. 5A), in TNF treated myoblasts. However, at 24 and 48 hrs no
evidence of DNA methylation was detected within the TSS (data not
shown). We therefore asked whether methylation could occur in a
moreselectiveregion.Insupportofthisnotion,wedetectedasmaller
CpG island (BS1) within region 105, which coincided with Ezh2
binding. ChIP analysis further revealed that methyltransferase
Dnmt-3b, but not Dnmt1 or 3a, was strongly recruited to region
105 following 48 hrs of TNF treatment (Fig. 5B). Dnmt-3b
recruitment was found to be dependent on Ezh2, since siRNA
silencing of Ezh2 prior to the addition of TNF led to a significant
reduction of Dnmt-3b binding to region 105 of the Notch-1
promoter (Fig. 5C). Together, these data indicated that DNA
methylation most likely occurs within the smaller BS1 CpG island.
Toconfirmthispossibility, C2C12 myoblasts were treatedwith TNF
and bisulfite sequencing was repeated on the BS1 region.
Significantly, an increase in methylation was detected in BS1
following TNF treatment. This regulation appeared specific since
methylation started after 4 days of treatment, and occurred at
discreteresidueswithin theBS1region(Fig.5D).Weinferfromthese
results that Notch-1 silencing occurs from a combination of Ezh2
Figure 2. TNF regulates Notch-1 expression in vivo. A. Muscle
homogenates were prepared from 7–8 week old mdx mice that either
contained or lacked IKKb and western analysis was performed probing
for Notch-1. The blot was stripped and reprobed for a-tubulin used as a
loading control. B. Nude mice were implanted with vector control CHO
cells or CHO cells expressing TNF. Once tumors were established,
muscle injury was induced to tibialis anterior muscles with cardiotoxin
injections. At indicated days post-toxin injections, muscles were
harvested and homogenates prepared for western analysis probing
for Notch-1 and a-tubulin as a loading control.
doi:10.1371/journal.pone.0012479.g002
Figure 3. TNF regulation of Notch-1 is dependent on NF-kB. A.
Western analysis of Notch-1 was performed in either untreated or TNF
treated C2C12 vector myoblasts or myoblasts stably expressing the
IkBa-SR transgene. B. C2C12 myoblasts were pre-treated for 1 hr with
either DMSO, an IKK inhibitor peptide (NBD) in both a wild type (wt)
and inactive mutant form (mut), or with a treatment of wortmannin.
Following TNF treatment, cells were harvested and western was
performed probing for Notch-1 and a-tubulin as a control.
doi:10.1371/journal.pone.0012479.g003
TNF Inhibition of Notch-1
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methylation occurs within the first 48 hrs, long-term suppression
of Notch-1 by TNF is maintained through Dnmt-3b methylation of
BS1 in the Notch-1 promoter that encompasses the same 105 region
of PcG binding. Thus, this may be one mechanism through which
TNF is capable of inhibiting Notch-1 expression and satellite cell
activation in mdx mice.
Discussion
Satellite cells and their descendant myoblast population remain
as a potential source of regeneration that can be harnessed
therapeutically in life threatening degenerative diseases such as
DMD [4]. As a step in furthering our understanding of satellite cell
regulation, this study explored how TNF in the muscle
environment represses the satellite cell program. The Notch
signaling pathway specifically plays a crucial role in satellite cell
activation, proliferation and self-renewal [26]. In line with studies
showing that the inhibition of the TNF signaling pathway is
beneficial in DMD [21,38,39,40], our findings elucidate a new
mode of action of TNF in downregulating Notch-1 that may be
relevant in muscular dystrophies.
Contrary to the most well studied mechanism of TNF mediated
transcriptional activation via NF-kB or c-jun/AP1 [9,10], this
Figure 4. TNF repression of Notch-1 occurs through the recruitment of Ezh2. A. Time course analysis of Notch-1 expression following TNF
treatment of C2C12 myoblasts. B. Schematic illustration of the Notch-1 gene indicating conserved regions of CpG content (blue bars) that are located
in positions proximal to the transcriptional start site (TSS), and where probes were designed for ChIP analysis. Also indicated is a CpG island
immediately surrounding the TSS (red bar). C, D. C2C12 myoblasts were treated with TNF and at indicated times cells were harvested and
subsequently prepared for ChIP analysis probing for Ezh2 by both semi-quantitative (C) and quantitative (D) RT-PCR. E. Using cell extracts prepared
in C, additional ChIPs were performed for methylation of H3K27. F. C2C12 myoblasts were transfected with scrambled siRNA (siControl) or siRNA
targeting Ezh2 (siEzh2) and following 48 hrs, western blot analyze was performed probing for Ezh2 and a-tubulin used as a loading control. G. C2C12
myoblasts transfections were performed with siControl and siEzh2 oligonucleotides and next day cells were treated for TNF for 48 hrs, and
subsequently processed for Notch-1 expression by real-time RT-PCR. Asterisks denotes p=0.00314).
doi:10.1371/journal.pone.0012479.g004
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be transcriptionally repressed in response to TNF. Our study
provides first time evidence that TNF silencing of Notch-1 in
muscle cells occurs epigenetically, by a concerted recruitment of
histone and DNA methyltransferases. TNF-mediated repression of
Notch-1 also appeared to require NF-kB activation. How NF-kB
is involved in regulating epigenetic repression of the Notch-1
promoter is not known at this time, yet several recent mechanisms
have been described to support a role for NF-kB in gene silencing.
In the presence of UV radiation and certain chemotherapeutic
drugs, NF-kB has been shown to repress anti-apoptotic genes such
as Bcl-XL and A20 by associating with histone deacetylases [41],
and in the context of myogenesis, our group has recently shown
that NF-kB can indirectly repress troponin-I2 and miR-29 by
transcriptionally activating the polycomb repressor, YY1 [19]. In
addition, based on work by Ndlovu and colleagues [42], NF-kB
was shown to increase chromatin accessibility across the IL-6
promoter in breast cancer cells. Hence, it can be speculated that
increased chromatin accessibility mediated by NF-kB can facilitate
binding of histone and DNA methylation complexes under certain
conditions.
Evidence exists in favor of histone and DNA methylation
preceding one another in diverse cell types and conditions [43,44].
In fact, gene silencing in many instances can also occur by either
histone or DNA methylation by mutually exclusive mechanisms
[45,46]. However, findings from the current study suggest a
sequential recruitment of the polycomb associated histone
methyltransferase, Ezh2, followed by DNA methyltransferase,
Figure 5. TNF promotes Dnmt-3b recruitment and DNA methylation on the Notch-1 promoter. A. Schematic illustration of the Notch-1
promoter indicating the CpG islands in the BS1 and BS2 regions proximal to the TSS. B. C2C12 myoblasts were treated with TNF for 48 hrs at which
time cells were prepared for quantitative ChIP analysis for Dnmt-1, Dnmt-3a, and Dnmt-3b. C. C2C12 myoblasts were transfected with scrambled
siRNA or siRNA against Ezh2 and the following day cells were treated for TNF for 48 hrs and ChIP analysis for Dnmt-3b was subsequently performed.
D. C2C12 myoblasts were treated with TNF for up to 7 days and at indicated times, cells were processed for bisulfite sequencing of the BS1 region
within the Notch-1 promoter. Note the increase in BS1 methylation at discrete CpG dinucleotides over time with TNF treatment.
doi:10.1371/journal.pone.0012479.g005
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cooperative relationship between the polycomb repressors, Ezh2,
Suppressor of Zeste12, and DNA methyltransferases has been
shown in HOXA9 gene silencing upon loss of p16
INK4a tumor
suppressor activity in breast cancer cells [47]. However, unlike the
HOXA9 locus, de-novo methylation on the Notch-1 promoter is
not as extensive and is restricted only to a few bases. The potential
reason behind selective methylation of the notch promoter in spite
of significant recruitment of Dnmt-3b upon TNF treatment is
currently unknown. Nonetheless, in favor of minimal methylation
mediating transcriptional repression, a few single sites of the p53
and rDNA promoters when methylated can effectively suppress
gene expression [48,49], and interestingly, Dnmt-3b was associ-
ated with methylation of discrete cytosine in non-CpG islands of
the peroxisome proliferator-activated receptor c coactivator-1a
promoter (50). Moreover, Ezh2 was also shown to directly interact
with DNMTs to repress certain genes such as MYT1 [37].
Whether a similar physical association can occur in muscle satellite
cells during TNF mediated repression of Notch-1 remains to be
elucidated.
In summary, based on our previous study [25] and current
findings, we envision that the NF-kB pathway functions to limit
muscle regeneration at multiple levels in the context of DMD.
Conditional deletion of the IKK/NF-kB pathway in mature
myofibers in mdx mice results in a reduction in TNF and an
increase in the number of satellite cells. One mechanism by which
TNF has been shown to be relevant in DMD is by promoting
muscle necrosis potentially through its inflammatory activity
[38,50]. We propose that an additional role for TNF in DMD is
to negatively regulate satellite cell activation through Notch-1
suppression. Interestingly, this TNF-mediated downregulation of
Notch levels is NF-kB dependent and additionally involves
epigenetic silencing by a combination of histone and DNA
methylation. Finally, given the relevance of TNF in several
pathophysiological states such as cancer and aging [51,52], and its
connection with the deregulation of the Notch signaling pathway
implicated in these diseases [26,53,54], suggests that the
significance of TNF regulation of Notch-1 may extend to tissues
other than skeletal muscle.
Materials and Methods
Cell culture
C2C12 cells were obtained from ATCC and cultured and
differentiated as described [17]. Generation of C2C12 myoblasts
stably expressing a wild type or mutated NF-kB luciferase reporter
and cells expressing the IkB-SR (super-repressor) transgene have
been previously described [16]. Transient transfections and
luciferase assays on C2C12 cells were performed as previously
described [19]. siRNA sequences targeting Ezh2 were transfected
as mixture using Lipofectamine 2000 following manufacturer’s
instructions [19]. Satellite cell and myoblast cultures were
prepared from whole muscles by isolating mononuclear cells from
2-day old neonates and performing pre-plating steps to remove
contaminating fibroblasts or by FACS sorting as described
[25,55,56,57].
Materials
Antibodies against total Notch-1, the intracellular domain of
Notch, and Delta were purchased from Santa Cruz Biotechnology.
Antibody for a-tubulin was obtained from Sigma, and for Numb
and Jagged from the Developmental Hybridoma Bank at Iowa. For
ChIP analysis, antibodies against mSin3A, histone deacetylase 1
(HDAC1), YY1 and Mi-2 were purchased from Santa Cruz
Biotechnology. Antibodies against Ezh2, and trimethyl-H3K27
were purchased from Cell Signaling, Zymed, and Upstate,
respectively. Antibodies against Dnmt-1, Dnmt-3a and Dnmt-3b
were purchased from Imgenex. Isotype immunoglobulin G (IgG;
Sigma) was used as negative control in ChIP analysis. For FACS,
CD34-Alexa Fluor 647 (Clone RAM34) was obtained from
Ebioscience, Ly-6A/E (Sca-1)-PE from BD Pharmingen, and a7-
integrin-FITC from MBL International. Human TNF was
purchased from Promega. Pharmacological inhibitors of NF-kB
and PI3K/Akt were purchased from Calbiochem and used as
described [58,59]. Wild type and mutant NBD peptides were a kind
gift from AS Baldwin (University Of North Carolina, Chapel Hill).
Trichostatin A was purchased from ICN Biomedical, dissolved in
ethanol and used as described [46]. Ezh2 Stealth RNAi, set of 3 (ID
no. MSS204098, MSS204099, and MSS204100), were obtained
from Invitrogen.
RNA and protein analysis
For RNA expression quantification, 400 ng of total purified
RNA was reverse transcribed using the first-strand synthesis
system (Roche), or for lower yields of RNA obtained from cell
sorting, cDNA synthesis was performed with the iScript kit
(BioRad). cDNA corresponding to approximately 5 ng of initial
RNA was next used for each quadruplicate quantitative PCR
reaction. Mouse Notch-1, Hey-1, Hes-1, and b-actin (as
endogenous control) were amplified using commercially designed
inventoried Taqman gene expression assays and Taqman
Universal PCR master mix (Applied Biosystems). Quantitative
RNA expression data were acquired and analyzed in 384-well-
plate format using an ABI Prism 7900HT Sequence Detection
System (Applied Biosystems) relative to endogenous control. For
western blot analysis, extracts were prepared in the presence of
protease inhibitors as previously described [16], and results are
representative of experiments repeated at a minimum of three
times.
Cell sorting
For FACS, limb muscles from 6-week old mdx mice were
minced and digested in PBS collagenase and dispase at 37uC with
agitation. DMEM-H with 10% heat activated horse serum was
used to stop enzymatic digestion and two sequential filtrations with
70 mm and 40 mm screens were performed. Cell pellets were then
resuspended in cold PBS containing 0.5% BSA and incubated
with primary antibodies for 30 min on ice. Flow cytometry
analysis and cell sorting were performed on a FACS Aria (Becton
Dickingson), with appropriate isotype matching controls. Sorted
CD34
+, a7integrin
+, Sca1
2 cells were then immediately placed in
culture with F10 medium containing 20% FBS and fibroblast
growth factor supplementation with or without TNF treatment for
24 hrs.
Mice
Mdx (C57/Bl/10 ScSn DMD
mdx) were purchased from The
Jackson Laboratory. IKK floxed mice and MLC-Cre mice were
used as previously described [60], [61] to generate mdx IKK floxed
and mdx IKK floxed- MLC cre mice. All the genotypes were
determined by PCR analysis from tail DNA. Mice were housed in
the animal facilities of The Ohio State University Comprehensive
Cancer Center under conventional conditions with constant
temperature and humidity and fed a standard diet. All animal
experimentation were approved by The Ohio State University
Animal Care and Use Committee. For cardiotoxin experiments,
100 mlo f1 0mM cardiotoxin dissolved in PBS was injected into the
TNF Inhibition of Notch-1
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either an empty vector or TNF [17].
ChIP analysis
Chromatin immunoprecipitation were performed as described
[62]. Briefly, cells were cross-linked and soluble chromatin with an
average size of 200–1000 bp were prepared by sonication. Pre-
cleared soluble chromatin was incubated with 5 mg of antibodies.
Immunoprecipitated DNA-protein complexes were washed exten-
sively, eluted and de-crosslinked. Precipitated DNA was further
purified with PCR purification according to manufacturer’s
instructions (Qiagen). Samples were analyzed by real-time PCR
by the Universal Probe library (Roche) using the Faststart Taqman
Master kit (Roche) for the Notch-1 promoter. The threshold for
the promoter was adjusted by that of input values and represented
as relative enrichment. All quantitative PCRs were analyzed by
melting curve analysis and agarose gels to confirm the presence of
a specific single band. Data presented are representative of assays
repeated a minimum of three times.
Bisulfite sequencing
Bisulfite sequencing was performed as described in [63]. Briefly,
DNA was isolated from C2C12 myoblasts using QIAmp DNA
minikit and 0.5 mg from each sample was treated with sodium
bisulfite using EZ DNA Methylation kit (ZYMO Research).
Primer sequences were designed using Methyl Primer Express
Software v1.0 (Applied biosystems). Primer sequences and
amplification conditions are available upon request. Amplified
products were electrophoresed on 2% agarose gels and visualized
with ethidium bromide. PCR products were cloned into TOPO
TA cloning kit (Invitrogen). Six to ten randomly picked clones
were sequenced using ABI 3730 DNA analyzer (Applied
Biosystems) and analyzed using the BiQ Analyzer.
Statistical Analysis
All quantitative data are represented as mean 6 SEM unless
mentioned. Analysis was performed between different groups
using 2-tailed student’s t-test and nonparametric Mann-Whitney
U test. Statistical significance was set at a value of p,0.05.
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